Regeneron Pharmaceuticals
(REGN)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 1,920,700 | 2,602,000 | 2,730,000 | 2,152,300 | 1,937,200 |
| Marketable Securities | 7,888,300 | 7,917,500 | 8,114,800 | 7,761,300 | 6,990,500 |
| Receivables | 5,717,100 | 5,222,200 | 5,667,300 | 5,584,500 | 5,121,300 |
| Inventories | 2,873,600 | 2,714,900 | 2,580,500 | 2,562,000 | 2,507,700 |
| TOTAL | $19,081,600 | $18,871,500 | $19,479,200 | $18,634,800 | $16,923,000 |
| Non-Current Assets | |||||
| PPE Net | 4,305,900 | 4,225,500 | 4,146,400 | 4,006,100 | 3,922,600 |
| Investments And Advances | 7,722,400 | 6,978,800 | 5,396,500 | 5,778,500 | 6,327,200 |
| Intangibles | 1,102,200 | 1,058,700 | 1,038,600 | 1,017,200 | 953,000 |
| Other Non-Current Assets | 3,874,700 | 3,235,100 | 3,019,500 | 2,726,700 | 2,531,700 |
| TOTAL | $17,005,200 | $15,498,100 | $13,601,000 | $13,528,500 | $13,734,500 |
| Total Assets | $36,086,800 | $34,369,600 | $33,080,200 | $32,163,300 | $30,657,500 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 561,700 | 671,300 | 606,600 | 536,600 | 547,300 |
| Accrued Expenses | 2,360,900 | 2,392,900 | N/A | N/A | N/A |
| Other current liabilities | N/A | N/A | 2,357,900 | 2,644,700 | 2,176,000 |
| TOTAL | $3,508,600 | $3,580,900 | $3,423,400 | $3,598,600 | $3,104,400 |
| Non-Current Liabilities | |||||
| Long Term Debt | 1,983,600 | 1,983,300 | 1,982,900 | 1,982,600 | 1,982,200 |
| Deferred Revenues | 586,000 | 516,700 | 458,900 | 417,300 | 381,100 |
| Other Non-Current Liabilities | 1,463,200 | 908,500 | 854,100 | 832,400 | 716,800 |
| TOTAL | $4,372,400 | $3,797,600 | $3,683,700 | $3,660,300 | $3,535,200 |
| Total Liabilities | $7,881,000 | $7,378,500 | $7,107,100 | $7,258,900 | $6,639,600 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 110,235 | 110,186 | 109,762 | 108,947 | 108,559 |
| Common Shares | 100 | 100 | 100 | 100 | 100 |
| Retained earnings | 29,414,600 | 27,982,300 | 27,260,300 | 26,100,700 | 25,092,900 |
| Other shareholders' equity | -69,800 | -76,900 | -81,300 | -176,900 | -197,600 |
| TOTAL | $28,205,800 | $26,991,100 | $25,973,100 | $24,904,400 | $24,017,900 |
| Total Liabilities And Equity | $36,086,800 | $34,369,600 | $33,080,200 | $32,163,300 | $30,657,500 |